HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combo Products Guidance Could Help Point Novel OTC Switches In Right Direction

This article was originally published in The Tan Sheet

Executive Summary

FDA delivers a draft GMPs guidance for combination products, providing details and examples on how the agency regulates drug delivery devices and other drug/device products. The document could be useful for firms interested in proposing novel Rx-to-OTC switches.


Related Content

Industry Seeks More Clarity Following Combo Product GMP Final Rule
FDA Aims To “NSURE” Clarity About New Paradigm For OTC Switches
Combination Products Offer Regulatory Option For Novel Switches
FDA To Tackle Critical Generics Issue In Switch Paradigm Debate





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts